New York State Common Retirement Fund decreased its position in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 16.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 39,939 shares of the biotechnology company's stock after selling 7,700 shares during the period. New York State Common Retirement Fund owned 0.05% of Axon Enterprise worth $15,960,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently bought and sold shares of AXON. Blue Trust Inc. lifted its stake in shares of Axon Enterprise by 987.5% in the 2nd quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company's stock valued at $27,000 after purchasing an additional 79 shares during the last quarter. Quent Capital LLC boosted its stake in shares of Axon Enterprise by 1,875.0% during the 3rd quarter. Quent Capital LLC now owns 79 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 75 shares in the last quarter. Asset Dedication LLC acquired a new position in shares of Axon Enterprise during the 2nd quarter valued at about $47,000. Friedenthal Financial bought a new position in shares of Axon Enterprise in the 3rd quarter valued at approximately $51,000. Finally, Cullen Frost Bankers Inc. acquired a new stake in Axon Enterprise in the 2nd quarter worth approximately $59,000. Hedge funds and other institutional investors own 79.08% of the company's stock.
Axon Enterprise Price Performance
NASDAQ AXON traded up $18.43 on Wednesday, reaching $459.52. The company's stock had a trading volume of 723,956 shares, compared to its average volume of 521,086. The firm has a market cap of $34.73 billion, a PE ratio of 116.38, a price-to-earnings-growth ratio of 10.99 and a beta of 0.94. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. Axon Enterprise, Inc. has a 52 week low of $212.88 and a 52 week high of $462.64. The business has a 50-day moving average price of $405.32 and a 200 day moving average price of $343.13.
Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.18. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The business had revenue of $504.00 million during the quarter, compared to analysts' expectations of $478.35 million. During the same period in the prior year, the firm posted $0.80 EPS. Axon Enterprise's quarterly revenue was up 34.5% compared to the same quarter last year. Sell-side analysts expect that Axon Enterprise, Inc. will post 1.79 EPS for the current year.
Analyst Ratings Changes
A number of equities analysts have recently commented on the stock. Jefferies Financial Group started coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They issued a "buy" rating and a $385.00 price target on the stock. Bank of America began coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They set a "buy" rating and a $380.00 target price for the company. Needham & Company LLC raised their price target on Axon Enterprise from $400.00 to $525.00 and gave the company a "buy" rating in a research report on Tuesday, October 22nd. Craig Hallum boosted their price objective on Axon Enterprise from $370.00 to $376.00 and gave the stock a "buy" rating in a research report on Wednesday, August 7th. Finally, Barclays raised their target price on Axon Enterprise from $381.00 to $387.00 and gave the company an "overweight" rating in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat.com, Axon Enterprise has an average rating of "Moderate Buy" and an average price target of $392.85.
Read Our Latest Report on Axon Enterprise
Insiders Place Their Bets
In other news, President Joshua Isner sold 25,811 shares of the business's stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $359.84, for a total value of $9,287,830.24. Following the sale, the president now owns 228,166 shares in the company, valued at approximately $82,103,253.44. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Axon Enterprise news, Director Matthew R. Mcbrady sold 2,000 shares of Axon Enterprise stock in a transaction on Friday, August 9th. The stock was sold at an average price of $364.66, for a total value of $729,320.00. Following the completion of the transaction, the director now owns 4,892 shares in the company, valued at approximately $1,783,916.72. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, President Joshua Isner sold 25,811 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $359.84, for a total value of $9,287,830.24. Following the sale, the president now owns 228,166 shares in the company, valued at $82,103,253.44. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 371,172 shares of company stock worth $137,000,162 over the last three months. 5.70% of the stock is currently owned by corporate insiders.
Axon Enterprise Profile
(
Free Report)
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Further Reading
Before you consider Axon Enterprise, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axon Enterprise wasn't on the list.
While Axon Enterprise currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.